

Julia A Elvin

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2144157/julia-a-elvin-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

60
papers

2,613
citations

24
h-index

51
g-index

62
ext. papers

3,503
ext. citations

6.7
avg, IF

4.28
L-index

#	Paper	IF	Citations
60	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. <i>Cancer Discovery</i> , 2018 , 8, 822-835	24.4	648
59	Comprehensive Analysis of Hypermutation in Human Cancer. <i>Cell</i> , 2017 , 171, 1042-1056.e10	56.2	417
58	The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. <i>International Journal of Cancer</i> , 2016 , 138, 881-90	7.5	168
57	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies. <i>JAMA Oncology</i> , 2015 , 1, 40-49	13.4	137
56	Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. <i>Clinical Cancer Research</i> , 2016 , 22, 6061-6068	12.9	81
55	High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis. <i>Cancer Research</i> , 2017 , 77, 2464-2475	10.1	71
54	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. <i>Oncologist</i> , 2015 , 20, 1132-9	5.7	69
53	Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling. <i>European Urology</i> , 2016 , 70, 516-21	10.2	61
52	Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials. <i>Oncologist</i> , 2016 , 21, 684-91	5.7	61
51	Comprehensive genomic profiling of inflammatory breast cancer cases reveals a high frequency of clinically relevant genomic alterations. <i>Breast Cancer Research and Treatment</i> , 2015 , 154, 155-62	4.4	57
50	STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 66	22.4	56
49	Comprehensive Genomic Profiling of Advanced Penile Carcinoma Suggests a High Frequency of Clinically Relevant Genomic Alterations. <i>Oncologist</i> , 2016 , 21, 33-9	5.7	55
48	Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling. <i>European Urology</i> , 2018 , 73, 71-78	10.2	54
47	Fusions in a Wide Variety of Tumor Types Respond to Anti-ALK Targeted Therapy. <i>Oncologist</i> , 2017 , 22, 1444-1450	5.7	50
46	FGFR3-TACC3: A novel gene fusion in cervical cancer. <i>Gynecologic Oncology Reports</i> , 2015 , 13, 53-6	1.3	43
45	Comprehensive genomic profiling of extrahepatic cholangiocarcinoma reveals a long tail of therapeutic targets. <i>Journal of Clinical Pathology</i> , 2016 , 69, 403-8	3.9	40
44	Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy. <i>Journal of Urology</i> , 2019 , 201, 541-548	2.5	36

43	Comprehensive genomic profiling of malignant phyllodes tumors of the breast. <i>Breast Cancer Research and Treatment</i> , 2017 , 162, 597-602	4.4	31
42	Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy. <i>Cancer</i> , 2017 , 123, 3628-3637	6.4	30
41	Tumor Mutational Burden Guides Therapy in a Treatment Refractory Mutant Uterine Carcinosarcoma. <i>Oncologist</i> , 2018 , 23, 518-523	5.7	30
40	Correlation Between Molecular Subclassifications of Clear Cell Renal Cell Carcinoma and Targeted Therapy Response. <i>European Urology Focus</i> , 2016 , 2, 204-209	5.1	30
39	A recurrent endometrial stromal sarcoma harbors the novel fusion. <i>Gynecologic Oncology Reports</i> , 2017 , 20, 51-53	1.3	26
38	Use of comprehensive genomic profiling to direct point-of-care management of patients with gynecologic cancers. <i>Gynecologic Oncology</i> , 2016 , 141, 2-9	4.9	26
37	Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options. <i>Oncologist</i> , 2017 , 22, 834-842	5.7	26
36	Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). <i>Nature Communications</i> , 2021 , 12, 2487	17.4	24
35	Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing. <i>Clinical Cancer Research</i> , 2016 , 22, 3281-5	12.9	22
34	Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	22
33	Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. <i>European Urology</i> , 2020 , 77, 548-556	10.2	19
32	Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy. <i>Gynecologic Oncology</i> , 2019 , 154, 461-466	4.9	19
31	reversion mutation acquired after treatment identified by liquid biopsy. <i>Gynecologic Oncology Reports</i> , 2017 , 21, 57-60	1.3	19
30	Personalized Treatment for a Patient With a BRAF V600E Mutation Using Dabrafenib and a Tumor Treatment Fields Device in a High-Grade Glioma Arising From Ganglioglioma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 1345-1350	7.3	18
29	Comprehensive genomic profiling (CGP) of ovarian clear cell carcinomas (OCCC) identifies clinically relevant genomic alterations (CRGA) and targeted therapy options. <i>Gynecologic Oncology Reports</i> , 2017 , 20, 62-66	1.3	14
28	General paucity of genomic alteration and low tumor mutation burden in refractory and metastatic hepatoblastoma: comprehensive genomic profiling study. <i>Human Pathology</i> , 2017 , 70, 84-91	3.7	13
27	Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 405-13	4.4	13
26	Elevated tumor mutational burden and prolonged clinical response to anti-PD-L1 antibody in platinum-resistant recurrent ovarian cancer. <i>Gynecologic Oncology Reports</i> , 2017 , 21, 78-80	1.3	13

25	Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors. <i>European Urology Focus</i> , 2019 , 5, 748-755	5.1	11
24	Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. <i>Modern Pathology</i> , 2020 , 33, 2397-2406	9.8	9
23	Melanomas with activating RAF1 fusions: clinical, histopathologic, and molecular profiles. <i>Modern Pathology</i> , 2020 , 33, 1466-1474	9.8	9
22	Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. <i>Gynecologic Oncology</i> , 2020 , 156, 32-37	4.9	9
21	Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Origin: Retrospective Molecular Classification Considering the CUPISCO Study Design. <i>Oncologist</i> , 2021 , 26, e394-e402	5.7	9
20	in Lung Cancers: Analysis of Patient Cases Reveals Recurrent Mutations, Fusions, Kinase Duplications, and Concurrent Alterations. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	8
19	Vulvar Squamous Cell Carcinoma: Comprehensive Genomic Profiling of HPV+ Versus HPV- Forms Reveals Distinct Sets of Potentially Actionable Molecular Targets. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	7
18	Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing. <i>Oncologist</i> , 2018 , 23, 776-781	5.7	7
17	TMPRSS2-ERG fusions unexpectedly identified in men initially diagnosed with nonprostatic malignancies. <i>JCO Precision Oncology</i> , 2017 , 2017,	3.6	6
16	Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification. <i>Oncoscience</i> , 2015 , 2, 581-4	0.8	6
15	A metastatic colon adenocarcinoma harboring BRAF V600E has a durable major response to dabrafenib/trametinib and chemotherapy. <i>OncoTargets and Therapy</i> , 2015 , 8, 3561-4	4.4	6
14	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. <i>Cancer</i> , 2021 ,	6.4	6
13	CYLD-mutant cylindroma-like basaloid carcinoma of the anus: a genetically and morphologically distinct class of HPV-related anal carcinoma. <i>Modern Pathology</i> , 2020 , 33, 2614-2625	9.8	5
12	CYLD mutation characterizes a subset of HPV-positive head and neck squamous cell carcinomas with distinctive genomics and frequent cylindroma-like histologic features. <i>Modern Pathology</i> , 2021 , 34, 358-370	9.8	3
11	Clinicopathologic and genomic characterization of PD-L1-positive uterine cervical carcinoma. <i>Modern Pathology</i> , 2021 , 34, 1425-1433	9.8	3
10	Comprehensive genomic profiling aids in treatment of a metastatic endometrial cancer. <i>Journal of Physical Education and Sports Management</i> , 2018 , 4,	2.8	2
9	Comprehensive Genomic Profiling of 104 Rare Histiocytic and Dendritic Cell Neoplasms Reveals Shared and Distinct Targetable Genomic Alterations. <i>Blood</i> , 2019 , 134, 2541-2541	2.2	2
8	Genomic Landscape of Adult and Pediatric -Like B-Lymphoblastic Leukemia Using Parallel DNA and RNA Sequencing. <i>Oncologist</i> , 2019 , 24, 372-374	5.7	2

7	Genomic Profiling Reveals Medullary Thyroid Cancer Misdiagnosed as Lung Cancer. <i>Case Reports in Oncology</i> , 2018 , 11, 399-403	1	1
6	-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of β -Wild-Type Tumor With Frequent Genomic Alterations and 1p/19q-Codeletion. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	1
5	Clinical Implications of Genomic Loss of Heterozygosity in Endometrial Carcinoma. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	1
4	Clinical, histopathologic, and molecular profiles of PRKAR1A-inactivated melanocytic neoplasms. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1069-1071	4.5	1
3	Acid-Based Decalcification Methods Compromise Genomic Profiling from DNA and RNA. <i>Blood</i> , 2019 , 134, 4659-4659	2.2	0
2	Loss of Heterozygosity of FLT3-ITD Is Common in Acute Myeloid Leukemia and May be a More Consistent Prognostic Marker Than FLT3-ITD Allele Frequency. <i>Blood</i> , 2019 , 134, 1437-1437	2.2	0
1	Clinicopathologic and Genomic Characterization of PD-L1 Positive Urothelial Carcinomas. <i>Oncologist</i> , 2021 , 26, 375-382	5.7	0